Oxford Bioscience Partners Iv Lp - Net Worth and Insider Trading
Oxford Bioscience Partners Iv Lp Net Worth
The estimated net worth of Oxford Bioscience Partners Iv Lp is at least $56 Million dollars as of 2024-11-10. Oxford Bioscience Partners Iv Lp is the 10% Owner of ACADIA Pharmaceuticals Inc and owns about 3,160,238 shares of ACADIA Pharmaceuticals Inc (ACAD) stock worth over $56 Million. Details can be seen in Oxford Bioscience Partners Iv Lp's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Oxford Bioscience Partners Iv Lp has not made any transactions after 2005-04-20 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Oxford Bioscience Partners Iv Lp
Oxford Bioscience Partners Iv Lp Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Oxford Bioscience Partners Iv Lp owns 1 companies in total, including ACADIA Pharmaceuticals Inc (ACAD) .
Insider Ownership Summary of Oxford Bioscience Partners Iv Lp
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc | 2005-07-29 | 10 percent owner |
Oxford Bioscience Partners Iv Lp Latest Holdings Summary
Oxford Bioscience Partners Iv Lp currently owns a total of 1 stock. Oxford Bioscience Partners Iv Lp owns 3,160,238 shares of ACADIA Pharmaceuticals Inc (ACAD) as of April 20, 2005, with a value of $56 Million.
Latest Holdings of Oxford Bioscience Partners Iv Lp
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc | 2005-04-20 | 3,160,238 | 17.66 | 55,809,803 |
Holding Weightings of Oxford Bioscience Partners Iv Lp
Oxford Bioscience Partners Iv Lp Form 4 Trading Tracker
According to the SEC Form 4 filings, Oxford Bioscience Partners Iv Lp has made a total of 0 transactions in ACADIA Pharmaceuticals Inc (ACAD) over the past 5 years. The most-recent trade in ACADIA Pharmaceuticals Inc is the acquisition of 586,402 shares on April 20, 2005, which cost Oxford Bioscience Partners Iv Lp around $4 Million.
Insider Trading History of Oxford Bioscience Partners Iv Lp
- 1
Oxford Bioscience Partners Iv Lp Trading Performance
GuruFocus tracks the stock performance after each of Oxford Bioscience Partners Iv Lp's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Oxford Bioscience Partners Iv Lp is 40.95%. GuruFocus also compares Oxford Bioscience Partners Iv Lp's trading performance to market benchmark return within the same time period. The performance of stocks bought by Oxford Bioscience Partners Iv Lp within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Oxford Bioscience Partners Iv Lp's insider trading performs compared to the benchmark.
Performance of Oxford Bioscience Partners Iv Lp
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 12.31 | | | | | |
| Relative Return to S&P 500(%) | 7.76 | | | | | |
Oxford Bioscience Partners Iv Lp Ownership Network
Ownership Network List of Oxford Bioscience Partners Iv Lp
Ownership Network Relation of Oxford Bioscience Partners Iv Lp
Oxford Bioscience Partners Iv Lp Owned Company Details
What does ACADIA Pharmaceuticals Inc do?
Who are the key executives at ACADIA Pharmaceuticals Inc?
Oxford Bioscience Partners Iv Lp is the 10 percent owner of ACADIA Pharmaceuticals Inc. Other key executives at ACADIA Pharmaceuticals Inc include EVP & COO & Head of Commercial Brendan Teehan , Chief Financial Officer Mark C. Schneyer , and director & PRESIDENT AND CEO Stephen Davis .
ACADIA Pharmaceuticals Inc (ACAD) Insider Trades Summary
Over the past 18 months, Oxford Bioscience Partners Iv Lp made no insider transaction in ACADIA Pharmaceuticals Inc (ACAD). Other recent insider transactions involving ACADIA Pharmaceuticals Inc (ACAD) include a net sale of 54,525 shares made by Mark C. Schneyer , a net sale of 319,936 shares made by Stephen Davis , and a net sale of 41,903 shares made by Brendan Teehan .
In summary, during the past 3 months, insiders sold 51,014 shares of ACADIA Pharmaceuticals Inc (ACAD) in total and bought 0 shares, with a net sale of 51,014 shares. During the past 18 months, 455,345 shares of ACADIA Pharmaceuticals Inc (ACAD) were sold and 896,522 shares were bought by its insiders, resulting in a net purchase of 441,177 shares.
ACADIA Pharmaceuticals Inc (ACAD)'s detailed insider trading history can be found in Insider Trading Tracker table.
ACADIA Pharmaceuticals Inc Insider Transactions
Oxford Bioscience Partners Iv Lp Mailing Address
Above is the net worth, insider trading, and ownership report for Oxford Bioscience Partners Iv Lp. Currently GuruFocus does not have mailing address information for Oxford Bioscience Partners Iv Lp.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
